Alembic Settles Dementia Drug Patent Dispute With Novartis

by Kathy Jones on  June 16, 2012 at 10:35 PM Medico Legal News
RSS Email Print This Page Comment bookmark
Font : A-A+

Indian drug maker Alembic Pharmaceuticals revealed that it has settled a patent case with Novartis over Rivastigmine Tartrate capsules which are used in treating dementia.
 Alembic Settles Dementia Drug Patent Dispute With Novartis
Alembic Settles Dementia Drug Patent Dispute With Novartis

The company said that it had partnered an American company, Breckenridge Pharmaceuticals, in settling the Paragraph IV patent litigation with Novartis.

Following this settlement, Alembic Pharmaceuticals said Novartis has given them the license to market the generic version of capsules before the date of the patent expiry.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Alzheimers Disease Drug Toxicity Signature Drug Toxicity Dementia Vascular Dementia 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...